Archives
- 2026-10
- 2026-09
- 2026-08
- 2026-07
- 2026-06
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
EZ Cap™ Human PTEN mRNA: Translational Strategy
2026-08-11
A mechanistic and strategic guide to using EZ Cap™ Human PTEN mRNA (ψUTP) as an in vitro transcribed mRNA tool for restoring PTEN biology, interrogating PI3K/Akt signaling, and designing translational cancer research programs around therapeutic resistance.
PTEN mRNA Nanoparticles Reverse Trastuzumab Resistance
2026-08-10
Dong and colleagues developed tumor-microenvironment-responsive nanoparticles for systemic PTEN mRNA delivery in trastuzumab-resistant HER2-positive breast cancer. The study links conditional nanoparticle uptake and restored PTEN expression to PI3K/Akt signaling pathway inhibition, providing a mechanistically focused strategy for re-sensitizing tumors to trastuzumab.
ω-Agatoxin IVA TFA: Assay Design Guide
2026-08-09
Learn how ω-Agatoxin IVA TFA (SKU C8722) can improve mechanistic interpretation in neuronal calcium, synaptic transmission, and viability workflows. This scenario-based guide explains concentration selection, Cav2.1 subtype interpretation, storage, and vendor-selection criteria using current structural evidence.
ECL Western Blotting Substrate: Workflow Guide
2026-08-08
ECL Western Blotting Substrate (SKU K2187) is a luminol-based, nonradioactive horseradish peroxidase detection reagent for chemiluminescent Western blot assays. It is intended for HRP-mediated immunoblot imaging with film or CCD systems, not for fluorescent or radioisotopic detection workflows.
ω-Agatoxin IVA and Cortical Excitotoxicity
2026-08-07
Lustig, Ahern, and Greenberg tested whether selective P/Q-type calcium-channel blockade could protect cortical neurons from excitotoxic injury. Their negative result shows that inhibiting toxin-sensitive calcium channels or presynaptic glutamate release is not, by itself, sufficient to prevent acute neuronal damage in this culture model.
AICAR and Mitophagy: Precision Tools for Metabolic Stress Re
2026-08-07
Explore how AICAR (5-aminoimidazole-4-carboxamide-1-beta-4-ribofuranoside) enables targeted dissection of AMPK-dependent mitophagy for metabolic disease research. This article uniquely bridges recent mechanistic insights to practical assay optimization.
10 mM dNTP Mixture: Precision DNA Synthesis for Modern Workf
2026-08-06
APExBIO’s 10 mM dNTP (2'-deoxyribonucleoside-5'-triphosphate) Mixture stands as a benchmark DNA synthesis reagent, enabling high-fidelity PCR, qPCR, and sequencing with exceptional reproducibility. Its equimolar, pH-stabilized formulation simplifies complex experimental designs and empowers cutting-edge nucleic acid delivery research.
Metformin Hydrochloride: Protocol Innovations for Fibrosis &
2026-08-06
Metformin Hydrochloride (Metformin HCl) is redefining fibrosis and metabolic pathway research by enabling precise AMPK pathway modulation and inhibition of hepatic gluconeogenesis. This guide bridges cutting-edge findings with actionable protocols, troubleshooting insights, and comparative applications for advanced bench workflows.
Berberrubine's Role in NAFLD: Glucose, Lipid, and Microbiota
2026-08-05
Yang et al. demonstrate that berberrubine, a principal metabolite of berberine, alleviates non-alcoholic fatty liver disease (NAFLD) by modulating glucose and lipid metabolism and restoring gut microbiota balance. This research provides mechanistic insights with translational potential for metabolic liver disease intervention.
BKT140 (BL-8040): Transforming CXCR4-Driven Cancer Research
2026-08-05
Discover how BKT140 (BL-8040), a potent CXCR4 antagonist, is reshaping the landscape of tumor progression and stem cell mobilization studies. This article delivers in-depth insight into its mechanism, assay optimization, and evolving role in oncology research.
ω-Agatoxin IVA Suppresses Seizures and Modulates BDNF/Caspas
2026-08-04
This study demonstrates that the P/Q-type calcium channel blocker ω-Agatoxin IVA significantly delays seizure onset and modulates neuroprotective markers in a rat epilepsy model. The findings highlight a mechanistically distinct approach to anticonvulsant and neuroprotective research, with translational implications for synaptic transmission and neuronal survival.
DeferoxamineB in Cancer Research: Protocols, Workflows, and
2026-08-04
Deferoxamine (DeferoxamineB) enables precision iron chelation and the fine-tuning of regulated cell death in experimental oncology, with applications spanning ferroptosis, autophagy, and apoptosis assays. This guide distills the latest workflow enhancements, troubleshooting strategies, and emerging cross-domain insights, helping researchers maximize both assay reliability and translational impact.
3-Deazaneplanocin (DZNep): Reliable Epigenetic Modulator for
2026-08-03
This article offers scenario-driven, evidence-based guidance for using 3-Deazaneplanocin (DZNep, SKU A1905) in cell-based assays targeting oncology and metabolic disease models. With a focus on protocol optimization, reproducibility, and vendor reliability, it empowers researchers to maximize data quality and workflow efficiency.
Silybin A in Silymarin: Translational Leverage for Liver Dis
2026-08-03
This thought-leadership article explores the mechanistic and strategic landscape of Silybin A—a principal flavonolignan in Silymarin—focusing on its antioxidant, anti-inflammatory, and hepatoprotective mechanisms relevant to advanced liver disease and metabolic research. It synthesizes biochemical insight, protocol guidance, and translational strategy, offering a roadmap for researchers seeking rigor and impact in hepatoprotection and metabolic modulation studies.
M344 Histone Deacetylase Inhibitor: Protocols and Innovation
2026-08-02
M344 stands out as a potent, cell-permeable histone deacetylase inhibitor, enabling advanced cancer and HIV latency research with unmatched precision. This article delivers actionable protocols, experimental insights, and troubleshooting strategies that maximize the value of M344 in epigenetic and oncology workflows.
8500 records 9/567 page Previous Next First page 上5页 678910 下5页 Last page